» Articles » PMID: 21324900

Casein Kinase 1-dependent Phosphorylation of Familial Advanced Sleep Phase Syndrome-associated Residues Controls PERIOD 2 Stability

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2011 Feb 18
PMID 21324900
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian circadian clock component PERIOD2 (PER2) plays a critical role in circadian rhythm entrainment. Recently, a missense mutation at a putative phosphorylation site in hPER2, Ser-662, was identified in patients that suffer from familial advanced sleep phase syndrome (FASPS). Patients with FASPS display abnormal sleep-wake patterns characterized by a lifelong pattern of sleep onset in the early evening and offset in the early morning. Although the phosphorylation of PER2 is strongly implied from functional studies, it has not been possible to study the site-specific phosphorylation of PER2 on Ser-662, and the biochemical functions of this residue are unclear. Here, we used phospho-specific antibodies to show that PER2 is phosphorylated on Ser-662 and flanking casein kinase (CK) sites in vivo. The phosphorylation of PER2 was carried out by the combined activities of casein kinase 1δ (CK1 δ) and casein kinase 1ε (CK1ε) and was antagonized by protein phosphatase 1. PER2 phosphorylation was rapidly induced in response to circadian entrainment of mammalian cell lines and occurred in both cytosolic and nuclear compartments. Importantly, we found that the pool of Ser-662-phosphorylated PER2 proteins was more stable than the pool of total PER2 molecules, implying that the FASPS phosphorylation cluster antagonizes PER2 degradation. Consistent with this idea, a Ser-662→Ala mutation that abrogated PER2 phosphorylation significantly reduced its half-life, whereas a phosphomimetic Ser-662→Asp substitution led to an elevation in half-life. Our combined findings provide new insights into PER2 regulation and the biochemical basis of FASPS.

Citing Articles

Targeting the circadian modulation: novel therapeutic approaches in the management of ASD.

Zhang Y, Chen Y, Li W, Tang L, Li J, Feng X Front Psychiatry. 2024; 15:1451242.

PMID: 39465045 PMC: 11503653. DOI: 10.3389/fpsyt.2024.1451242.


The Function, Regulation, and Mechanism of Protein Turnover in Circadian Systems in and Other Species.

Zhang H, Zhou Z, Guo J Int J Mol Sci. 2024; 25(5).

PMID: 38473819 PMC: 10931572. DOI: 10.3390/ijms25052574.


Circadian neurogenetics and its implications in neurophysiology, behavior, and chronomedicine.

Naveed M, Chao O, Hill J, Yang Y, Huston J, Cao R Neurosci Biobehav Rev. 2023; 157:105523.

PMID: 38142983 PMC: 10872425. DOI: 10.1016/j.neubiorev.2023.105523.


Quantitative Trait Locus Determining the Time of Blood Feeding in Culex pipiens (Diptera: Culicidae).

Hickner P, Mori A, Rund S, Severson D J Med Entomol. 2022; 59(5):1500-1506.

PMID: 35976948 PMC: 9473656. DOI: 10.1093/jme/tjac118.


PERIOD Phosphoclusters Control Temperature Compensation of the Circadian Clock.

Joshi R, Cai Y, Xia Y, Chiu J, Emery P Front Physiol. 2022; 13:888262.

PMID: 35721569 PMC: 9201207. DOI: 10.3389/fphys.2022.888262.


References
1.
Eide E, Woolf M, Kang H, Woolf P, Hurst W, Camacho F . Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Mol Cell Biol. 2005; 25(7):2795-807. PMC: 1061645. DOI: 10.1128/MCB.25.7.2795-2807.2005. View

2.
Reddy A, Karp N, Maywood E, Sage E, Deery M, ONeill J . Circadian orchestration of the hepatic proteome. Curr Biol. 2006; 16(11):1107-15. DOI: 10.1016/j.cub.2006.04.026. View

3.
Xu Y, Padiath Q, Shapiro R, Jones C, Wu S, Saigoh N . Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005; 434(7033):640-4. DOI: 10.1038/nature03453. View

4.
Albrecht U, Bordon A, Schmutz I, Ripperger J . The multiple facets of Per2. Cold Spring Harb Symp Quant Biol. 2008; 72:95-104. DOI: 10.1101/sqb.2007.72.001. View

5.
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler H . The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22(3):375-82. DOI: 10.1016/j.molcel.2006.03.038. View